
    
      This is an open-label study intended to evaluate the relative bioavailability of 4 Probuphine
      implants versus 16mg QD sublingual buprenorphine, as determined by plasma BPN AUC(0-24),
      during 24 hours at steady state. This study will also provide open-label safety and
      tolerability data in patients treated with Probuphine.
    
  